Selected current trials in T-cell ALL in adolescent and adult patients
| Trial group/trial . | Description of study . | Population . | Primary end point . | Trial # . |
|---|---|---|---|---|
| UKALL 14 (UK NCRI) | Phase 3 nelarabine in induction randomization | Adults aged 25-65 y with de novo ALL | EFS | NCT01085617 |
| UKALL 2011 (UK NCRI) | Phase 3 randomized comparison of dexamethasone and methotrexate schedules | Children and young adults up to 25 y with de novo ALL and LBL | Steroid-related toxicity; CNS and marrow relapse rate | ISRCTN64515327 |
| MD Anderson | Phase 2 nelarabine/HyperCVAD | Children and adults | CR | NCT00501826 |
| US Intergroup | Pediatric-like regimen | 21-40 y | Survival | NCT00558519 |
| DFCI | LY3039478 (notch inhibitor) | Relapsed/refractory disease; 2 y and older | Overall remission rate | NCT02518113 |
| GRAALL | Pediatric-like regimen | Adults (median age, 31 y) | EFS | NCT00327678 |
| NCI | Phase 3, bortezomib randomization | 18 y and older | EFS | NCT02112916 |
| GIMEMA | Phase 2, lineage-targeted methotrexate dosing | 18-65 y | EFS | NCT02067143 |
| Trial group/trial . | Description of study . | Population . | Primary end point . | Trial # . |
|---|---|---|---|---|
| UKALL 14 (UK NCRI) | Phase 3 nelarabine in induction randomization | Adults aged 25-65 y with de novo ALL | EFS | NCT01085617 |
| UKALL 2011 (UK NCRI) | Phase 3 randomized comparison of dexamethasone and methotrexate schedules | Children and young adults up to 25 y with de novo ALL and LBL | Steroid-related toxicity; CNS and marrow relapse rate | ISRCTN64515327 |
| MD Anderson | Phase 2 nelarabine/HyperCVAD | Children and adults | CR | NCT00501826 |
| US Intergroup | Pediatric-like regimen | 21-40 y | Survival | NCT00558519 |
| DFCI | LY3039478 (notch inhibitor) | Relapsed/refractory disease; 2 y and older | Overall remission rate | NCT02518113 |
| GRAALL | Pediatric-like regimen | Adults (median age, 31 y) | EFS | NCT00327678 |
| NCI | Phase 3, bortezomib randomization | 18 y and older | EFS | NCT02112916 |
| GIMEMA | Phase 2, lineage-targeted methotrexate dosing | 18-65 y | EFS | NCT02067143 |
DFCI, Dana-Farber Cancer Institute; GIMEMA, Gruppo Italiano Malattie Ematologiche dell’Adulto; NCI, National Cancer Institute; UK NCRI, United Kingdom National Cancer Research Institute.